Thoracic Aortic Aneurysm & Dissection

Topic Overview

Summary

Thoracic aortic aneurysm (TAA) represents pathological dilatation of the thoracic aorta, defined as diameter exceeding 1.5 times the expected normal size for a given aortic segment, age, sex, and body size. The ascending aorta is most commonly affected, followed by the descending thoracic aorta. TAA may remain asymptomatic for years until catastrophic complications develop, including acute aortic dissection, rupture, or sudden death. Acute aortic dissection is a surgical emergency characterized by intimal tear and propagation of blood into the aortic media, creating a false lumen that can compromise branch vessels and lead to end-organ malperfusion. The classic presentation is sudden, severe "tearing" chest or interscapular back pain with radiation following the dissection path. [1,2]

Diagnosis relies on high clinical suspicion and rapid imaging with CT aortic angiography, which is the gold standard for emergency evaluation. Stanford classification guides management: Type A dissection (involving ascending aorta) requires emergency open surgical repair with mortality of 1-2% per hour if untreated, while uncomplicated Type B dissection (distal to left subclavian artery) is typically managed with aggressive medical therapy targeting heart rate and blood pressure control. Complicated Type B dissections benefit from thoracic endovascular aortic repair (TEVAR). [1,2,3]

Key Facts

• TAA definition: Aortic diameter > 4.0cm (ascending) or > 3.0cm (descending); normal ascending aorta measures 2.0-3.7cm depending on age, sex, and body surface area [1]
• Incidence of dissection: 5-30 cases per million population per year; Type A represents 60-65% of cases [4,5]
• Risk of rupture: Increases exponentially with diameter; 5-year rupture risk is 16% for 5.0-5.9cm TAA and 31% for 6.0cm or larger [6]
• Dissection presentation: Sudden severe "tearing" chest (Type A) or interscapular pain (Type B) in 85-90%; pulse asymmetry in 15-30% [7]
• Type A mortality: 1-2% per hour without surgery; 20-30% operative mortality even with emergency repair [8]
• Type B outcomes: 10% mortality for uncomplicated cases with medical management; 30-50% for complicated dissections [9]
• Imaging: CT aortic angiogram has 98-100% sensitivity and 95-98% specificity for acute aortic dissection [10]
• Surgical thresholds:
  • "Ascending TAA: ≥5.5cm (general population); ≥5.0cm (Marfan, bicuspid aortic valve, family history) [1]"
  • "Descending TAA: ≥6.0cm (general); ≥5.5cm (connective tissue disorder) [1]"
  • Growth rate ≥0.5cm/year warrants consideration for repair [1]

Clinical Pearls

Dissection mimics MI: Up to 10% of Type A dissections involve coronary ostia causing myocardial infarction; D-dimer is typically markedly elevated (> 1,600 ng/mL) in dissection but normal in uncomplicated MI—sensitivity 97% but specificity only 56%. [11,12]

Bilateral arm blood pressure: Systolic BP difference > 20 mmHg between arms has 31% sensitivity but 96% specificity for aortic dissection; absence does not rule out dissection. [7]

Time is aorta: Type A dissection mortality increases 1-2% per hour; median time to death is 3 days without surgery. Door-to-diagnosis time should be less than 60 minutes for suspected acute aortic syndrome. [8]

Marfan surgical threshold: Lower thresholds (≥4.5-5.0cm) recommended when aortic root Z-score ≥3, family history of dissection less than 5cm, rapid growth (> 3mm/year), or pregnancy planned. [13,14]

TEVAR timing: In complicated Type B dissection, early TEVAR (within 14 days) improves aortic remodeling and reduces long-term mortality compared to delayed intervention. [15]

Why This Matters Clinically

Acute aortic dissection is one of the most lethal cardiovascular emergencies, with untreated Type A dissection causing death in 50% of patients within 48 hours and 75% within 2 weeks. Misdiagnosis occurs in 15-40% of cases at initial presentation, often confused with acute coronary syndrome, pulmonary embolism, or musculoskeletal pain. [8,16] Delays in diagnosis directly translate to increased mortality, with each hour of delay increasing death risk by 1-2%. Early recognition of red flags, rapid imaging, and immediate surgical consultation are lifesaving. For unruptured TAA, elective repair before dissection or rupture occurs offers excellent outcomes, with operative mortality less than 5% at high-volume centers. [1,17]

---

Visual Summary

Visual assets to be added:

• Thoracic aorta anatomical segments (ascending, arch, descending)
• Stanford Type A vs Type B classification diagram
• DeBakey classification (Types I, II, III) illustration
• CT angiogram showing intimal flap and true/false lumens
• CXR showing widened mediastinum (> 8cm at T4 level)
• Aortic diameter measurement technique
• Malperfusion syndrome schema
• TEVAR procedure illustration

---

Epidemiology

Thoracic Aortic Aneurysm

Prevalence and Incidence

Thoracic aortic aneurysms affect approximately 10-15 per 100,000 person-years, with prevalence increasing with age. Population-based studies demonstrate TAA prevalence of 0.16-0.34% in screening cohorts. [4,18] The ascending aorta is involved in 40-50% of cases, aortic arch in 10-15%, and descending thoracic aorta in 35-40%. Approximately 25% of patients have multi-segment involvement. [1,18]

Demographics

• Age: Peak incidence 60-75 years; mean age at diagnosis 65-70 years
• Sex: Male:female ratio 2-3:1 for degenerative TAA; ratio approaches 1:1 in genetic syndromes [4,18]
• Geographic variation: Higher rates in Northern European populations; lower in Asian populations
• Temporal trends: Incidence increasing due to improved imaging detection and aging populations [18]

Acute Aortic Dissection

Incidence

Acute aortic dissection occurs in 5-30 cases per million population per year, with higher rates in Japan (40-43 per million). [4,5] In the United States, approximately 10,000-20,000 cases occur annually. Autopsy studies suggest significant underdiagnosis, with dissection found in up to 1-2% of all autopsies. [5,19]

Classification Distribution

• Stanford Type A: 60-65% of all dissections
• Stanford Type B: 35-40% of all dissections
• DeBakey Type I: 50-60% (ascending + descending)
• DeBakey Type II: 10-15% (ascending only)
• DeBakey Type III: 25-35% (descending only) [1,7]

Demographics

• Age: Peak incidence 60-70 years; mean age 63 years for Type A, 67 years for Type B [5]
• Sex: Male predominance (2-3:1) for degenerative dissections; genetic syndromes affect sexes equally
• Circadian pattern: Peak occurrence 6 AM to 12 PM, correlating with morning BP surge [20]
• Seasonal variation: Higher incidence in winter months and with temperature fluctuations [20]

Risk Factors

---

Pathophysiology

Molecular Mechanisms of Aneurysm Formation

Cystic Medial Degeneration

The hallmark pathological finding in TAA is cystic medial degeneration, characterized by fragmentation and loss of elastic fibers, smooth muscle cell apoptosis, and accumulation of basophilic ground substance in the aortic media. This process weakens the aortic wall, reducing tensile strength and predisposing to progressive dilatation. [32,33]

Key molecular mechanisms include:

1. Extracellular matrix degradation: Increased matrix metalloproteinase (MMP) activity, particularly MMP-2 and MMP-9, degrades elastin and collagen. Tissue inhibitors of metalloproteinases (TIMPs) are downregulated, shifting the balance toward proteolysis. [32,33]

2. Transforming growth factor-β (TGF-β) dysregulation: Paradoxically, both excessive and deficient TGF-β signaling contribute to aortopathy. In Marfan syndrome, fibrillin-1 mutations lead to TGF-β activation, causing aberrant smooth muscle cell signaling and matrix degradation. In Loeys-Dietz syndrome, TGF-β receptor mutations cause constitutive pathway activation. [14,24,34]

3. Smooth muscle cell dysfunction: Loss of contractile phenotype, increased apoptosis, and defective matrix synthesis impair aortic wall structural integrity. [33]

4. Hemodynamic stress: Ascending aorta experiences highest hemodynamic forces during ventricular ejection, with wall tension proportional to diameter and pressure (Laplace's law: Tension = Pressure × Radius). Progressive dilatation creates a positive feedback loop of increasing wall stress. [35]

Genetic Contributions

Approximately 20% of TAA cases have a familial component, with autosomal dominant inheritance patterns. [27] Key genetic syndromes include:

• Marfan syndrome (FBN1): Fibrillin-1 deficiency disrupts microfibril assembly and increases TGF-β signaling [13,14]
• Loeys-Dietz syndrome (TGFBR1, TGFBR2): Direct TGF-β receptor mutations [24]
• Vascular Ehlers-Danlos syndrome (COL3A1): Type III collagen deficiency causes arterial fragility [25]
• Bicuspid aortic valve-associated aortopathy (NOTCH1, others): Shared embryologic defect affects valve and ascending aorta [22,23]
• Familial TAAD (ACTA2, MYH11, MYLK, others): Smooth muscle contractile protein mutations [27]

Dissection Mechanism

Acute aortic dissection occurs when blood enters the aortic media through an intimal tear, propagating along the length of the aorta and creating a blood-filled space (false lumen) separate from the true lumen. [2,7]

Initiating Factors

1. Intimal tear: Occurs at sites of maximal hemodynamic shear stress:

   • Right lateral ascending aorta (65%)
   • Proximal descending aorta just distal to left subclavian artery (20%)
   • Aortic arch (10%)
   • Abdominal aorta (5%) [7]

2. Hypertension: Sudden BP elevation increases wall stress, precipitating intimal disruption. Present in 65-75% of dissection patients. [5,7]

3. Pre-existing medial degeneration: Weakened aortic media facilitates dissection propagation.

Propagation and Complications

Once initiated, the dissection propagates both antegrade (toward aortic bifurcation) and retrograde (toward aortic root). The false lumen typically spirals around the true lumen, with the intimal flap acting as a mobile membrane. [2,7]

Mechanisms of end-organ injury:

1. Static obstruction: Intimal flap directly occludes branch vessel ostia
2. Dynamic obstruction: Flap mobility causes intermittent occlusion during cardiac cycle
3. Branch vessel involvement: Dissection extends into branch artery
4. Hypotension: Cardiac tamponade, acute aortic regurgitation, or rupture reduces perfusion pressure [2,7]

Malperfusion Syndromes

Malperfusion occurs in 30-40% of acute aortic dissections, significantly worsening prognosis. [36]

Natural History of Untreated TAA

Growth rates vary by location, etiology, and patient factors:

• Degenerative ascending TAA: 0.07-0.19 cm/year (median 0.1 cm/year) [6]
• Degenerative descending TAA: 0.19-0.29 cm/year (median 0.2 cm/year) [6]
• Marfan syndrome TAA: 0.3-0.5 cm/year, faster in younger patients [13,14]
• Post-dissection chronic aneurysm: 0.3-0.7 cm/year [9]

Rupture and dissection risk correlates with size [6]:

• 4.0-4.9 cm: 5-year event rate 4%
• 5.0-5.9 cm: 5-year event rate 16%
• ≥6.0 cm: 5-year event rate 31%

---

Clinical Presentation

Thoracic Aortic Aneurysm (Unruptured)

Most TAAs are asymptomatic and discovered incidentally on imaging performed for other indications. Symptoms, when present, typically reflect mass effect on adjacent structures or herald impending rupture. [1,18]

Symptomatic TAA

Acute Aortic Dissection

Acute aortic dissection presents with sudden onset of severe symptoms in 85-95% of cases. The classic triad of sudden severe chest pain, pulse differential, and widened mediastinum occurs in only 25-30% of patients. [7,8]

Pain Characteristics

Pain is absent in 5-15% of cases, particularly in elderly patients, diabetics, or those presenting with complications (stroke, syncope, cardiac arrest). [7,8]

Associated Symptoms and Signs

Red Flags Requiring Immediate Evaluation

---

Clinical Examination

Vital Signs and Initial Assessment

Blood Pressure Measurement

• Bilateral arm BP: Measure in both arms simultaneously or sequentially. Systolic BP difference > 20 mmHg suggests subclavian involvement (31% sensitivity, 96% specificity for dissection). [7]
• All four extremities: If dissection suspected, measure BP in all extremities to identify extent of malperfusion.
• Patterns:
  • "Hypertension (SBP > 150 mmHg): 50-70% of cases, especially Type B [7]"
  • "Hypotension (SBP less than 90 mmHg): 20-30%, suggests tamponade, rupture, or severe AR; associated with 3-fold increased mortality [8]"
  • "Pseudo-hypotension: False low reading due to subclavian obstruction; measure in other limb [7]"

Heart Rate

• Tachycardia common (60-70% of cases) due to pain, catecholamine surge, or hypovolemia
• Bradycardia may indicate cardiac tamponade physiology or vagal response to pain

Cardiovascular Examination

Neurological Examination

Critical to assess for malperfusion syndromes, present in 10-20% of dissections: [7,36]

• Stroke: Hemiparesis, aphasia, visual field defects (carotid involvement)
• Spinal cord ischemia: Lower extremity weakness, sensory level, bowel/bladder dysfunction (intercostal artery occlusion)
• Horner syndrome: Ptosis, miosis, anhidrosis (sympathetic chain involvement)
• Altered consciousness: Ranges from confusion to coma (cerebral hypoperfusion or stroke)
• Peripheral neuropathy: Rare, from nerve root compression

Abdominal Examination

• Peritoneal signs: Rigidity, guarding, rebound tenderness suggest mesenteric ischemia (5-10% of dissections) [7,36]
• Pulsatile mass: May indicate extension into abdominal aorta
• Abdominal bruit: Renal artery involvement
• Oliguria/anuria: Renal malperfusion

Respiratory Examination

• Pleural effusion: More common in Type B; usually left-sided; may indicate impending rupture [7]
• Hemoptysis: Aorto-bronchial fistula (rare, life-threatening)
• Stridor: Tracheal compression from arch aneurysm

---

Investigations

Initial Emergency Workbench

For suspected acute aortic dissection, rapid diagnostic workup is essential. Target door-to-imaging time less than 60 minutes for suspected acute aortic syndrome. [1,2]

Laboratory Tests

12-Lead Electrocardiogram

ECG findings in aortic dissection are non-specific but important for differential diagnosis: [7]

• Normal ECG: 35-40% of cases
• Non-specific ST-T changes: 40-50%
• Left ventricular hypertrophy: 25-30% (chronic hypertension)
• ST-elevation MI pattern: 5-10% (coronary ostial involvement, usually RCA)
• Electrical alternans: Rare but specific for tamponade
• Low voltage: Pericardial effusion

Clinical Pearl: ECG may mislead toward primary ACS diagnosis. Always consider dissection in chest pain differential, especially with atypical features.

Chest X-Ray

CXR is abnormal in 60-90% of acute dissections but lacks sensitivity and specificity to rule in or rule out dissection. Normal CXR does not exclude dissection. [10]

Utility: CXR is useful for excluding alternative diagnoses (pneumothorax, pneumonia) and identifying patients needing advanced imaging, but cannot definitively diagnose or exclude dissection.

Definitive Imaging

CT Aortic Angiography (CTA)

Gold standard for emergency evaluation of suspected acute aortic dissection. [1,2,10]

Performance characteristics:

• Sensitivity: 98-100%
• Specificity: 95-98%
• Accuracy: 97-99%

Protocol: ECG-gated CT angiogram from thoracic inlet to femoral arteries with arterial phase imaging. Non-contrast images obtained first to identify intramural hematoma and high-attenuation blood.

Key findings:

1. Intimal flap: Linear filling defect separating true and false lumens (diagnostic hallmark)
2. True lumen: Often compressed, enhances early, has continuity with undissected aorta
3. False lumen: Often larger, enhances late, may contain thrombus, cobweb sign
4. Entry and exit tears: Sites of communication between lumens
5. Branch vessel involvement: Determines malperfusion risk
6. Pericardial/pleural effusion: Suggests impending or contained rupture
7. Coronary ostial involvement: Critical for surgical planning

Advantages:

• Rapid (5-10 minutes)
• Widely available
• High accuracy
• Defines full extent of disease
• Identifies malperfusion

Limitations:

• Contrast nephropathy risk (unavoidable in emergency)
• Radiation exposure
• Requires patient transport to CT scanner
• Cannot assess aortic valve function

Transesophageal Echocardiography (TEE)

Role: Alternative to CTA when CT unavailable or contraindicated; useful in operating room for intra-operative assessment. [1,38]

Performance characteristics:

• Sensitivity: 95-98% (ascending aorta and descending thoracic aorta)
• Specificity: 90-95%
• Accuracy: 92-97%

Advantages:

• Performed at bedside (no patient transport)
• No radiation or contrast
• Assesses aortic valve function and severity of regurgitation
• Detects pericardial effusion and tamponade
• Real-time imaging

Limitations:

• Semi-invasive (requires esophageal intubation)
• Operator-dependent
• Blind spot in distal ascending aorta and proximal arch (tracheal air artifact)
• Limited assessment of branch vessels
• Cannot image abdominal aorta

Clinical application: TEE particularly useful in hemodynamically unstable patients who cannot be transported to CT scanner, or in operating room for surgical planning and assessment of repair.

Magnetic Resonance Angiography (MRA)

Role: Excellent for surveillance of chronic dissections and TAA; rarely used in acute setting due to time requirements and limited availability. [1]

Performance characteristics:

• Sensitivity: 95-98%
• Specificity: 95-98%
• Accuracy: 96-98%

Advantages:

• No radiation
• No iodinated contrast (gadolinium-based)
• Multiplanar imaging
• Excellent soft tissue contrast
• Gold standard for aortic dimensions

Limitations:

• Time-consuming (45-60 minutes)
• Limited availability, especially emergently
• Requires patient cooperation (breath-holding)
• Contraindicated with pacemakers/ICDs (most devices)
• Cannot monitor unstable patients adequately

Clinical application: MRA is preferred for long-term surveillance in young patients requiring serial imaging (radiation minimization), pregnant patients (no radiation), and CKD patients (gadolinium safer than iodinated contrast in stage 3B+ CKD).

Transthoracic Echocardiography (TTE)

Role: Limited for diagnosing dissection but useful for assessing complications. [1,38]

Performance:

• Sensitivity: 60-80% (highly operator and patient-dependent)
• Specificity: 85-95%

Utility:

• Assess for pericardial effusion and tamponade
• Evaluate aortic regurgitation severity
• Measure ascending aortic root and proximal ascending aorta
• Assess left ventricular function

Limitations: Poor visualization of most of thoracic aorta; cannot reliably exclude dissection.

Surveillance Imaging Protocols

For patients with known TAA not meeting surgical criteria, serial imaging monitors growth and identifies indication for intervention. [1]

Imaging Intervals by Size

Growth Rate Thresholds

• Rapid growth: ≥0.5 cm/year in ascending aorta or ≥0.5 cm/year in descending aorta warrants surgical evaluation [1]
• Accelerating growth: Increasing growth rate over time is concerning even if absolute growth less than 0.5 cm/year

---

Classification & Staging

Stanford Classification

Most clinically useful classification system, guiding acute management decisions. [1,2,7]

Clinical Pearl: Any dissection involving ascending aorta is Type A and requires emergency surgery, even if entry tear is located in descending aorta with retrograde propagation.

DeBakey Classification

More anatomically detailed but less commonly used for acute management. [7]

Penn Classification (ABC)

Recently proposed classification incorporating presence of intramural hematoma and penetrating atherosclerotic ulcer:

• Class A: Classic dissection with intimal tear and flap
• Class B: Intramural hematoma without intimal flap
• Class C: Discrete intimal disruption (penetrating ulcer, traumatic, iatrogenic)

Complicated vs Uncomplicated Type B Dissection

Critical distinction for management strategy. [9,15]

Complicated Type B Dissection (requires TEVAR or open surgery)

• Malperfusion: End-organ ischemia (renal, mesenteric, limb, spinal)
• Rupture: Hemothorax, mediastinal hematoma, or extravasation on imaging
• Rapid expansion: Aortic diameter increase on serial imaging
• Refractory pain: Despite adequate analgesia and BP control
• Refractory hypertension: Uncontrollable despite maximal medical therapy
• Retrograde Type A: Type B dissection extending retrograde into ascending aorta (requires surgery)

Uncomplicated Type B Dissection (medical management)

• Pain controlled with analgesia
• Blood pressure controlled with medications
• No evidence of malperfusion
• No rupture or impending rupture
• Stable aortic dimensions

Outcomes: Uncomplicated Type B has 10% 30-day mortality with medical management; complicated Type B has 30-50% mortality. Early TEVAR for complicated Type B reduces mortality compared to medical management alone. [9,15]

---

Management

General Principles

1. Type A dissection is a surgical emergency: Immediate cardiothoracic surgery consultation; mortality increases 1-2% per hour [8]
2. Stabilize before imaging: Only in hemodynamically unstable patients; otherwise proceed directly to CTA
3. Blood pressure and heart rate control: Reduce aortic wall stress and dissection propagation [1,2]
4. Malperfusion identification: Determines surgical approach and urgency [36]
5. Multidisciplinary team: Cardiothoracic surgery, vascular surgery, interventional radiology, cardiac anesthesia, intensive care [1]

Immediate Stabilization (All Suspected Dissections)

Hemodynamic Goals

Target parameters to reduce aortic wall stress: [1,2]

• Heart rate: less than 60 bpm (reduces dP/dt and wall shear stress)
• Systolic blood pressure: 100-120 mmHg (balances end-organ perfusion with dissection propagation risk)
• Mean arterial pressure: 60-75 mmHg

CRITICAL: Beta-blockade must precede vasodilators to prevent reflex tachycardia, which increases wall shear stress.

Pharmacological Regimen

Monitoring

• Continuous telemetry and pulse oximetry
• Arterial line for beat-to-beat BP monitoring (place in right radial artery if dissection suspected; verify pulses bilaterally)
• Foley catheter for urine output (goal > 0.5 mL/kg/hr)
• Serial neurological exams for malperfusion detection

Initial Resuscitation Caveats

DO NOT:

• Give thrombolytics if STEMI pattern on ECG (may represent coronary malperfusion from dissection)
• Delay imaging for BP control unless patient in extremis
• Over-resuscitate with IV fluids if hypotensive (may increase BP and propagate dissection)

DO:

• Verify pulses in all extremities before placing arterial line
• Check BP in both arms; use higher reading as reference
• Maintain index of suspicion for tamponade (hypotension + elevated JVP + muffled heart sounds)

Type A Dissection Management

Emergency Open Surgical Repair

Indications: ALL Stanford Type A dissections require emergency surgery unless patient has explicitly refused or has unsurvivable comorbidities. [1,8]

Timing: Immediate transfer to operating room once diagnosis confirmed. Mortality increases 1-2% per hour; median survival without surgery is 3 days. [8]

Surgical Procedure (varies by anatomy and surgeon preference): [1,8,37]

1. Ascending aorta replacement: Resection of intimal tear and replacement with Dacron graft
2. Aortic root replacement:
   • Composite valve-graft (Bentall procedure) if severe AR or annular dilatation
   • Valve-sparing root replacement (David or Yacoub procedure) if valve competent
3. Hemiarch or total arch replacement: If tear involves arch or extensive arch involvement
4. Coronary reimplantation: If root replaced
5. Arch vessel reimplantation: If arch replaced

Intraoperative considerations:

• Cardiopulmonary bypass via femoral or axillary artery cannulation
• Deep hypothermic circulatory arrest for arch work
• Antegrade or retrograde cerebral perfusion for brain protection
• TEE for valve assessment and de-airing

Operative Mortality: 15-30% at experienced centers; higher at low-volume centers (less than 5 cases/year have 2-fold higher mortality). [1,8,17]

Predictors of mortality:

• Age > 70 years
• Shock or tamponade at presentation
• Malperfusion (especially mesenteric)
• Rupture
• Prior cardiac surgery
• Renal failure

Long-term Survival:

• 5-year survival: 60-70%
• 10-year survival: 40-50%
• Death due to: late rupture (15-20%), re-dissection (10-15%), heart failure (20-30%), other cardiovascular causes

Type B Dissection Management

Management strategy depends on whether dissection is complicated or uncomplicated. [9,15]

Uncomplicated Type B: Medical Management

Initial Therapy (intensive care unit): [1,9]

1. Beta-blockade + vasodilator: As per hemodynamic goals above
2. Pain control: Adequate analgesia to reduce sympathetic surge
3. Serial imaging: Repeat CTA at 24-48 hours to assess stability, then at discharge, 3 months, 6 months, and annually

Transition to Oral Therapy: Once patient stable (typically 48-72 hours):

Outcomes:

• 30-day mortality: 10%
• 1-year survival: 85-90%
• 5-year survival: 70-80%
• 20% develop aneurysmal degeneration requiring surgery within 5 years [9]

Complicated Type B: Endovascular or Surgical Repair

Indications for TEVAR or open surgery: [9,15]

1. Malperfusion (30-40% of Type B dissections):

   • Renal: oliguria, rising creatinine
   • Mesenteric: abdominal pain, peritoneal signs, lactate elevation
   • Limb: ischemic pain, absent pulses
   • Spinal: paraplegia, lower extremity weakness

2. Rupture or impending rupture:

   • Hemothorax
   • Periaortic hematoma
   • Extravasation of contrast

3. Rapid aortic expansion: Diameter increase on serial imaging

4. Refractory pain: Despite adequate analgesia and BP control

5. Refractory hypertension: Uncontrollable with maximal medical therapy

TEVAR Procedure (preferred for most complicated Type B): [15,40]

• Endovascular stent-graft covers proximal entry tear
• Promotes false lumen thrombosis and aortic remodeling
• Performed via femoral artery access under general anesthesia
• Requires adequate proximal and distal landing zones
• May require left subclavian artery coverage (revascularization if needed)

TEVAR Outcomes: [15,40]

• 30-day mortality: 5-10%
• Paraplegia risk: 2-5%
• Stroke risk: 3-5%
• Endoleak: 10-20% (requires surveillance and possible re-intervention)
• 5-year survival: 70-80%

Timing: Early TEVAR (within 14 days) associated with better aortic remodeling and lower late mortality compared to delayed intervention. [15]

Open Surgical Repair:

• Reserved for cases unsuitable for TEVAR (inadequate landing zones, severe tortuosity, connective tissue disorders with high risk of endoleak)
• Higher operative mortality (10-15%) but durable long-term results
• Requires thoracotomy or thoracoabdominal approach

Adjunctive Procedures for Malperfusion:

• Fenestration (create communication between true and false lumen to equalize pressure)
• Branch vessel stenting (renal, mesenteric, iliac arteries)
• Visceral debranching (surgical bypass to restore flow)

Subacute and Chronic Dissection Management

Subacute dissection (2-90 days after onset): Similar principles to acute phase but lower rupture risk. Medical management preferred for uncomplicated Type B; TEVAR for complicated features. [9]

Chronic dissection (> 90 days after onset):

• Aneurysmal degeneration occurs in 20-40% at 5 years [9]
• Surgical threshold: ≥5.5-6.0 cm maximum diameter
• TEVAR less effective (false lumen often thrombosed; challenging anatomy)
• Open repair often required for chronic degenerative aneurysms

Elective TAA Repair

For unruptured, undissected TAA, elective repair offers excellent outcomes when diameter exceeds risk thresholds. [1,17]

Indications for Elective Repair

Ascending Thoracic Aorta:

• Diameter ≥5.5 cm (general population) [1]
• Diameter ≥5.0 cm (bicuspid aortic valve, Marfan syndrome, Loeys-Dietz syndrome, family history of dissection) [1,13,14,22,23]
• Diameter ≥4.5 cm (if concomitant aortic valve surgery planned) [1]
• Growth rate ≥0.5 cm/year [1]
• Symptomatic aneurysm (any size if symptoms attributable to TAA)

Descending Thoracic Aorta:

• Diameter ≥6.0 cm (general population) [1]
• Diameter ≥5.5 cm (connective tissue disorder) [1]
• Growth rate ≥0.5 cm/year [1]
• Symptomatic aneurysm

Special Populations:

• Marfan syndrome: Lower thresholds; individualized based on family history, growth rate, aortic root Z-score; consider surgery at 4.5-5.0 cm if high-risk features [13,14]
• Loeys-Dietz syndrome: Even lower thresholds (4.0-4.5 cm) due to higher rupture risk at smaller diameters [24]
• Vascular Ehlers-Danlos (type IV): Surgery extremely high-risk due to tissue fragility; often managed medically unless rupture/dissection; consider TEVAR over open surgery [25]
• Bicuspid aortic valve: 5.0 cm threshold; lower (4.5 cm) if other risk factors (coarctation, family history) [22,23]
• Turner syndrome: Consider surgery at lower thresholds (4.5-5.0 cm) especially if other risk factors present [26]

Surgical Approaches

Ascending aorta and root: [1,17,37]

• Median sternotomy
• Cardiopulmonary bypass
• Options: supracoronary graft, root replacement (composite valve-graft or valve-sparing), hemiarch/total arch replacement
• Operative mortality: 2-5% at high-volume centers

Aortic arch:

• Median sternotomy
• Total arch replacement with elephant trunk or frozen elephant trunk technique
• Deep hypothermic circulatory arrest with cerebral protection
• Operative mortality: 5-10%

Descending thoracic aorta: [1,17,40]

• TEVAR (preferred if anatomy suitable): Percutaneous femoral access; stent-graft deployment; operative mortality 2-5%; paraplegia risk 2-5%; stroke risk 2-4%; 5-year survival 70-80%
• Open repair (if TEVAR unsuitable): Thoracotomy; cross-clamping or left heart bypass; operative mortality 5-15%; paraplegia risk 5-10%; durable long-term results

Volume-outcome relationship: Centers performing > 20 TAA repairs annually have 40-50% lower mortality compared to low-volume centers (less than 5 cases/year). [17] ACC/AHA guidelines recommend referral to high-volume centers when feasible. [1]

Medical Therapy for TAA (Non-operative Management)

For patients with small TAA not meeting surgical criteria, or post-operative, lifelong medical therapy aims to slow growth and prevent dissection. [1,39]

Beta-Blockade

Mechanism: Reduces heart rate, contractility, and dP/dt (rate of pressure rise in aorta), thereby decreasing hemodynamic stress on aortic wall. [31,39]

Evidence:

• Landmark study in Marfan syndrome demonstrated beta-blockers slow aortic root growth and reduce dissection risk [41]
• Benefit likely extends to other TAA etiologies, though less robust data
• Targets: HR less than 60 bpm; SBP less than 120 mmHg

Agents:

• Metoprolol succinate XL 50-200 mg daily
• Atenolol 25-100 mg daily
• Carvedilol 6.25-25 mg BID (additional alpha-blockade)

Angiotensin Receptor Blockers (ARBs)

Mechanism: Blocks angiotensin II type 1 receptor; reduces TGF-β signaling and matrix metalloproteinase activity; theoretical benefit on aortic wall remodeling. [34,39]

Evidence:

• Mixed results in clinical trials; some studies show benefit in Marfan syndrome, others show no difference compared to beta-blockers alone [34,39,42]
• May be particularly beneficial in connective tissue disorders with TGF-β dysregulation [34]
• Current guidelines suggest ARBs as alternative or addition to beta-blockers [1]

Agents:

• Losartan 50-100 mg daily (most studied in Marfan syndrome)
• Telmisartan 40-80 mg daily
• Valsartan 80-320 mg daily

ACE Inhibitors

Mechanism: Similar to ARBs; blocks angiotensin II formation; additional benefit via bradykinin pathway. [39]

Evidence: Less studied than ARBs for TAA; likely similar benefit.

Agents:

• Lisinopril 10-40 mg daily
• Ramipril 5-10 mg daily

Statins

Mechanism: Pleiotropic anti-inflammatory effects; reduce matrix metalloproteinase expression. [39]

Evidence:

• Observational data suggest statins may slow TAA growth [39]
• No randomized controlled trials
• Reasonable to prescribe for cardiovascular risk reduction in TAA patients

Blood Pressure Goals

• Target BP less than 130/80 mmHg for all TAA patients [1]
• Stricter control (less than 120/80 mmHg) may be beneficial, especially in connective tissue disorders

Genetic Counseling and Family Screening

Up to 20% of TAA cases have familial component. [27] ACC/AHA guidelines recommend genetic counseling and testing for: [1]

1. TAA with family history of TAA, dissection, or sudden cardiac death
2. Syndromic features: Marfan, Loeys-Dietz, Ehlers-Danlos, Turner
3. Young age (less than 50 years) with TAA
4. Bicuspid aortic valve with TAA

First-degree relatives of patients with TAA should undergo:

• Clinical evaluation for syndromic features
• Echocardiography or CTA to screen for TAA
• Genetic counseling if proband has identified mutation

Surveillance of affected family members:

• Annual imaging if TAA detected
• Earlier and more frequent if connective tissue disorder or rapid growth

Special Populations

Pregnancy

Pregnancy increases dissection risk, especially in Marfan syndrome and other connective tissue disorders. 50% of aortic dissections in women less than 40 years occur during pregnancy or early postpartum period. [30]

Pre-conception counseling:

• Imaging to establish baseline aortic dimensions
• Prophylactic aortic root repair if diameter ≥4.0-4.5 cm (Marfan) before pregnancy [13,30]
• High-risk if aortic root > 4.0 cm (Marfan) or > 4.5 cm (other etiologies)

Management during pregnancy:

• Beta-blockers throughout pregnancy (atenolol avoided in first trimester; labetalol preferred)
• Serial echocardiography (every 4-12 weeks depending on size and syndrome)
• Vaginal delivery acceptable if aortic root less than 4.0 cm; cesarean section if ≥4.0 cm or rapid growth
• Avoid Valsalva during delivery (epidural, forceps/vacuum-assisted delivery)
• Postpartum surveillance for 6 months (continued high risk)

Athletes

Vigorous physical activity increases aortic wall stress. [31]

Recommendations: [1]

• Avoid isometric exercise (weight-lifting, wrestling) if TAA > 4.0 cm
• Avoid competitive contact sports if TAA present
• Moderate aerobic exercise permissible if TAA less than 4.5 cm and no connective tissue disorder
• Individualize based on TAA size, etiology, and growth rate

---

Complications

Of Acute Dissection

Of Surgical/Endovascular Treatment

---

Prognosis & Outcomes

Acute Aortic Dissection

Type A Dissection

Predictors of poor outcome:

• Age > 70 years (OR 2.5)
• Shock or tamponade (OR 3.0-4.0)
• Mesenteric malperfusion (OR 5.0-10.0)
• Coma or stroke (OR 3.0-5.0)
• Acute renal failure (OR 2.0)
• Prior cardiac surgery (OR 1.5-2.0)

Causes of late mortality:

• Late aortic rupture: 15-20%
• Re-dissection: 10-15%
• Heart failure: 20-30%
• Other cardiovascular: 20-30%
• Non-cardiovascular: 10-20%

Type B Dissection

Long-term complications:

• Aneurysmal degeneration: 20-40% at 5 years [9]
• Re-dissection: 5-10% at 5 years
• Late rupture: 10-15% at 5 years (if not repaired)

Elective TAA Repair

Excellent outcomes when performed electively at high-volume centers: [17]

Quality of life: Most patients return to baseline functional status within 6-12 months post-operatively.

Natural History (Untreated TAA)

5-year risk of rupture, dissection, or death based on diameter at baseline: [6]

Growth rate: Median 0.1 cm/year (ascending); 0.2 cm/year (descending); faster in Marfan syndrome (0.3-0.5 cm/year). [6,13]

---

Advanced Diagnostic Strategies

Risk Stratification Tools

ADD-RS (Aortic Dissection Detection Risk Score)

The ADD-RS is a validated clinical decision tool developed to stratify patients by pre-test probability of acute aortic dissection. It incorporates 3 categories of risk markers: [45,46]

High-risk conditions (1 point each):

• Marfan syndrome, Loeys-Dietz syndrome, or other connective tissue disorder
• Family history of aortic disease
• Known aortic valve disease
• Known thoracic aortic aneurysm
• Recent aortic manipulation (surgery, catheterization)

High-risk pain features (1 point each):

• Chest, back, or abdominal pain described as:
  • Abrupt onset
  • Severe intensity
  • Ripping or tearing quality

High-risk examination features (1 point each):

• Evidence of perfusion deficit (pulse deficit, systolic BP differential ≥20 mmHg, focal neurological deficit)
• New aortic insufficiency murmur
• Hypotension or shock

Risk stratification:

• 0 points: Low risk (0.3% prevalence of dissection)
• 1 point: Intermediate risk (5.3% prevalence)
• ≥2 points: High risk (40.3% prevalence)

Clinical application: Patients with ADD-RS ≥1 should undergo definitive imaging (CTA). Combining ADD-RS with D-dimer (\u003c500 ng/mL cutoff) in low-risk patients achieves 99.7% negative predictive value for excluding aortic dissection. [12,46]

Biomarkers for Acute Aortic Syndromes

Recent studies have identified novel biomarkers for TAA and dissection risk stratification: [48,50]

ADvISED Study (2018): Prospective multicenter validation of ADD-RS + D-dimer algorithm showed 99.7% NPV for excluding dissection in low-risk patients, potentially reducing imaging by 30-40%. [12,50]

Advanced Imaging Techniques

4D Flow MRI

Four-dimensional flow MRI captures time-resolved, three-directional velocity mapping throughout the cardiac cycle, enabling hemodynamic assessment of the thoracic aorta. [59]

Applications in TAA:

1. Wall shear stress mapping: Identifies regions of high hemodynamic stress predisposed to dissection [59]
2. Flow patterns: Detects abnormal flow jets, helical flow, vortex formation that accelerate aortic degeneration [59]
3. Predictive value: Regions of elevated wall shear stress correlate with future aneurysm growth and dissection location [59]

Future potential: May refine surgical thresholds beyond diameter alone by incorporating hemodynamic risk assessment. [59]

Genetic Testing and Precision Medicine

Recent advances in genomic medicine have transformed TAA diagnosis and management. [49,54,57]

Indications for genetic testing (per 2022 ACC/AHA Guidelines): [1,49]

1. TAA with syndromic features (Marfan, Loeys-Dietz, vascular Ehlers-Danlos, Turner syndrome)
2. Family history of TAA, dissection, or sudden cardiac death in first-degree relative
3. Young age (TAA diagnosed \u003c50 years without clear risk factors)
4. Bicuspid aortic valve with TAA (especially if familial)
5. Dissection at small diameter (Type A dissection at aortic diameter \u003c5.0 cm)
6. Multivessel aneurysms (TAA plus aneurysms in other arterial beds)

Major genes associated with TAA: [49,54,57]

Cascade screening: When pathogenic variant identified, first-degree relatives should undergo genetic testing and aortic imaging. [1,49]

---

Differential Diagnosis

Acute aortic dissection presents with diverse symptoms that overlap with other life-threatening conditions. Misdiagnosis occurs in 15-40% of cases at initial presentation. [16,45,46]

High-Priority Differentials

Key discriminators favoring dissection: [45,46]

1. Temporal profile: Sudden onset, maximal intensity immediately (85-90% of dissections)
2. Pain quality: Tearing, ripping, sharp (50% of dissections)
3. Pain migration: Follows dissection path from chest→back→abdomen (70%)
4. Pulse examination: Asymmetry, deficits (15-30% of dissections)
5. Blood pressure: Differential ≥20 mmHg between arms (30% sensitivity, 96% specificity)
6. Aortic regurgitation: New diastolic murmur (40-75% Type A)
7. Widened mediastinum: CXR finding (60-80%)
8. D-dimer: Markedly elevated (\u003e1,600 ng/mL) in dissection

Critical diagnostic pitfall: 10-15% of Type A dissections involve coronary ostia (usually right coronary artery), causing ST-elevation MI pattern on ECG. [7,45,50] DO NOT give thrombolytics for chest pain + ST elevation without excluding dissection if ANY atypical features present (sudden tearing pain, pulse deficit, widened mediastinum). Thrombolysis in unrecognized dissection is catastrophic.

---

Special Populations and Scenarios

Pregnancy-Associated Aortic Dissection

Pregnancy is a significant risk factor for aortic dissection, especially in women with underlying aortopathy. Approximately 50% of aortic dissections in women \u003c40 years occur during pregnancy or early postpartum period (within 6 months). [30,55]

Epidemiology

• Incidence: 4.5 per 100,000 pregnancies overall; much higher in women with Marfan syndrome (1% per pregnancy) or bicuspid aortic valve [30,55]
• Timing: Third trimester 50%; Postpartum (first 3 months) 33%; First/second trimester 17% [30,55]
• Type distribution: Type A 78%; Type B 22% (higher proportion of Type A than general population) [55]

Risk Factors Specific to Pregnancy

Management

Type A dissection: [30,55]

• Emergency surgery indicated
• Cesarean delivery: Performed first if fetus ≥28 weeks and viable
• Maternal mortality: 21-33% (higher than general population) [55]
• Fetal mortality: 10-24% [55]

Type B dissection (uncomplicated): [30,55]

• Medical management: Beta-blockers (labetalol preferred), target BP \u003c120/80 mmHg
• Serial imaging: Echocardiography or MRA every 4-12 weeks
• Cesarean delivery recommended if aortic diameter ≥4.0 cm [30]

Pre-conception counseling: Prophylactic aortic root replacement before pregnancy if aortic root \u003e4.0 cm (Marfan) or \u003e4.5 cm (other etiologies). [30]

Postpartum: High-risk period continues for 6 months (33% of pregnancy-associated dissections occur postpartum); continue beta-blockers; repeat imaging at 6 weeks and 6 months. [30,55]

Cocaine and Stimulant-Associated Dissection

Cocaine and other stimulant drugs (methamphetamine, synthetic cathinones) cause acute aortic dissection via hypertensive crisis and catecholamine surge. [29,45]

Epidemiology:

• 0.5-2% of all dissections
• Younger patients (mean age 40-45 years vs 63 years in non-cocaine dissections)
• Type B more common than Type A (60% vs 40%), opposite of general population [29]

Pathophysiology:

1. Acute hypertension: Cocaine blocks norepinephrine/dopamine reuptake, causing severe BP spikes (SBP \u003e200 mmHg common) [29]
2. Increased dP/dt: Augmented LV contractility increases rate of pressure rise, escalating aortic wall shear stress [29]
3. Chronic arteriopathy: Recurrent cocaine use causes endothelial dysfunction, inflammation, medial degeneration [29]

Management:

• Beta-blockade FIRST: Labetalol (combined alpha/beta blocker) preferred; avoid pure beta-blockers (risk of unopposed alpha stimulation)
• Benzodiazepines: For agitation, anxiety (reduces catecholamine levels)
• Avoid pure alpha-agonists initially: May worsen coronary vasospasm [29]
• Long-term: Substance abuse counseling and treatment; higher recurrence risk if cocaine use continues

Athletes and Exercise-Related Dissection

Strenuous physical activity, particularly isometric exercise (weightlifting, rowing) and contact sports, transiently increases aortic wall stress. [31]

2022 ACC/AHA Guidelines for athletes with TAA: [1,31]

Blood pressure during exercise: Systolic BP can exceed 200 mmHg during maximal weightlifting, rowing, high-intensity interval training. [31]

Recommendations: Annual imaging if diameter \u003c4.5 cm; every 6 months if 4.5-5.4 cm; genetic counseling for athletes with TAA \u003c50 years.

Aortic Dissection in the Elderly (\u003e75 Years)

Older adults represent a challenging subgroup with higher operative mortality but also higher mortality if untreated. [8,45]

Operative mortality (Type A repair): [8,45]

• Age 75-80: 25-35%
• Age \u003e80: 35-50%
• Age \u003c70: 15-25%

Predictors of poor outcome: Age \u003e70, shock/tamponade, malperfusion, comorbidities (CKD, COPD, prior stroke). [8]

Presentation: [8]

• More likely to present with atypical symptoms (syncope, altered consciousness, abdominal pain)
• Pain may be absent in 15-25% (vs 5-10% in younger patients)
• Higher rate of complications at presentation (stroke, coma, cardiac tamponade)

Decision-making: [8,45]

• Type A dissection: Age alone is not absolute contraindication to surgery; individualize based on functional status, comorbidities, patient wishes
• Uncomplicated Type A: consider surgery
• Complicated with coma/irreversible stroke: palliative care may be appropriate
• Type B dissection: Medical management strongly preferred unless complicated

---

Emerging Therapies and Future Directions

Pharmacological Advances

Recent studies explore novel therapies targeting aortic wall pathophysiology: [48,50]

Smooth Muscle Cell Stabilization:

• Doxycycline: Tetracycline antibiotic with MMP-inhibiting properties; trials in TAA ongoing [48]
• Statins: Pleiotropic anti-inflammatory effects; observational data suggest slower TAA growth [39,48]
• mTOR inhibitors (Sirolimus, Everolimus): Inhibit aberrant smooth muscle cell signaling in Marfan syndrome; early trials show promise [48]

TGF-β Modulation: [48]

• TGF-β neutralizing antibodies: Block excessive signaling in Loeys-Dietz, Marfan syndromes (Phase 2 studies ongoing)
• SMAD inhibitors: Downstream pathway blockade (experimental)

Gene Therapy: [48,49]

• CRISPR-Cas9 gene editing: Correct pathogenic FBN1, TGFBR mutations (pre-clinical)
• Exon skipping: Restore functional fibrillin-1 production in Marfan syndrome (experimental)
• Timeline: 10-20 years before clinical application likely

Endovascular Innovation

Branched and Fenestrated Stent-Grafts: [53]

• Indication: Aortic arch and thoracoabdominal aneurysms previously requiring open surgery
• Technology: Preformed side branches for arch vessels (innominate, carotid, subclavian); customized openings for visceral arteries
• Outcomes: 30-day mortality 5-10% (vs 10-20% for open repair); stroke risk 5-8%; branch vessel patency 90-95% at 2 years [53]

Dissection-Specific Endografts: [51,52]

• Innovation: Enhanced radial force to compress false lumen; longer length to cover multiple entry tears
• Evidence: Ongoing trials (STABLE trials) comparing dissection-specific vs standard TEVAR grafts [51,52]

Artificial Intelligence and Machine Learning

Applications: [50]

• Dissection risk prediction: Algorithms integrating clinical data, imaging, biomarkers to predict individual dissection risk
• Automated imaging analysis: Aortic segmentation, growth rate calculation, wall stress mapping
• Dissection detection: AI algorithms detecting intimal flap on CT with 95-98% sensitivity

Benefits: Reduce inter-observer variability, save radiologist time, standardize measurements.

Timeline: Some tools already FDA-approved; broader adoption over next 5-10 years.

Surgical Innovations

Minimally Invasive Aortic Surgery: [45]

• Techniques: Ministernotomy, right anterior thoracotomy, robot-assisted
• Benefits: Reduced pain, faster recovery, improved cosmesis, shorter hospital stay (4-6 days vs 7-10 days)
• Outcomes: Comparable mortality and morbidity to full sternotomy in experienced hands [45]

Frozen Elephant Trunk (FET): [45,50]

• Indication: Extensive Type A dissection involving arch and descending aorta
• Technique: Single-stage procedure combining open ascending/arch replacement + antegrade insertion of stent-graft into descending thoracic aorta
• Benefits: Single operation (vs staged); promotes false lumen thrombosis; facilitates future TEVAR extension; reduces late reoperation rate [45,50]
• Outcomes: 30-day mortality 8-15%; stroke 5-8%; paraplegia 3-5%; improved long-term aortic remodeling

---

Multidisciplinary Aortic Team Approach

The 2022 ACC/AHA Guidelines emphasize creation of multidisciplinary aortic teams at centers managing TAA and dissection. [1,45,46]

Core Team Composition

Team Functions

1. 24/7 Availability: Rapid response for acute dissection (goal: diagnosis to operative intervention \u003c4 hours for Type A) [1,45]
2. Multidisciplinary conferences: Weekly or biweekly case review for complex cases
3. Standardized protocols: Acute dissection diagnostic algorithm, hemodynamic management guidelines, imaging surveillance schedules [1,45]
4. Quality metrics and outcomes tracking: Mortality rates (risk-adjusted), complication rates, door-to-imaging time, door-to-OR time
5. Education and simulation: Team training for dissection management

Volume-Outcome Relationship

Multiple studies demonstrate superior outcomes at high-volume aortic centers: [17,45]

Guidelines recommendation: Transfer to high-volume aortic center when feasible, particularly for elective repair. For acute Type A dissection, immediate surgery at nearest capable center may be preferred over transfer if long distance. [1,45]

---

Viva Voce Preparation

High-Yield Examination Questions

Q1: "A 68-year-old man presents with sudden severe interscapular back pain. Describe your approach."

Model Answer:

• High suspicion for acute aortic syndrome (Type B dissection, intramural hematoma, penetrating atherosclerotic ulcer)
• Immediate assessment: ABCs, vital signs in both arms, pulse examination all extremities, cardiovascular/neurological examination
• Risk stratification: ADD-RS (risk factors, pain features, exam findings) - assess for high-risk conditions, high-risk pain, high-risk exam findings
• Initial investigations:
  • ECG (exclude ACS, look for ST elevation suggesting coronary involvement)
  • CXR (widened mediastinum \u003e8cm?)
  • D-dimer if low-intermediate risk (ADD-RS 0-1); \u003c500 ng/mL excludes dissection with 96% NPV
• Definitive imaging: CT aortogram (gold standard; 98-100% sensitivity, 95-98% specificity) - from thoracic inlet to femoral arteries
• Initial management:
  • "Hemodynamic control: Beta-blocker FIRST (esmolol, labetalol), THEN vasodilator if needed"
  • "Targets: HR \u003c60 bpm, SBP 100-120 mmHg"
  • Adequate analgesia (morphine, fentanyl)
  • Cardiothoracic/vascular surgery consultation immediately

Q2: "Describe the Stanford classification of aortic dissection and its clinical relevance."

Model Answer:

• Type A: Involves ascending aorta (regardless of entry tear location); 60-65% of all dissections

  • "Management: Emergency open surgical repair"
  • "Mortality: 1-2% per hour untreated; 50% dead at 48 hours; 75% at 2 weeks without surgery"
  • "Operative mortality: 15-30% even with emergency repair"
  • "Complications: Cardiac tamponade (10-15%), acute AR (40-75%), coronary malperfusion (10-15%), stroke (5-10%)"

• Type B: Does NOT involve ascending aorta; originates distal to left subclavian artery; 35-40% of dissections

  • "Management: Medical management if uncomplicated; TEVAR if complicated"
  • "Uncomplicated: Beta-blocker + vasodilator; 10% 30-day mortality; 85-90% 1-year survival"
  • "Complicated: Malperfusion, rupture, refractory pain/HTN, rapid expansion"
    • TEVAR reduces mortality vs medical alone
    • 10-15% 30-day mortality with TEVAR; 75-85% 1-year survival
    • 30-50% mortality with medical management alone (historical)

• Clinical relevance: Dictates management strategy; Type A is surgical emergency; Type B is medical emergency with selective endovascular intervention for complications

Q3: "Explain the molecular mechanisms underlying cystic medial degeneration in TAA."

Model Answer:

• Cystic medial degeneration = hallmark pathological finding in TAA
• Features: Elastic fiber fragmentation, smooth muscle cell apoptosis, accumulation of basophilic ground substance, loss of extracellular matrix integrity
• Molecular mechanisms:
  1. MMP dysregulation: Increased MMP-2/MMP-9 activity degrades elastin and collagen; reduced TIMPs shift balance toward proteolysis
  2. TGF-β pathway dysregulation:
     • Marfan (FBN1 mutations): Loss of fibrillin-1 → increased TGF-β activation → aberrant smooth muscle signaling, matrix degradation
     • Loeys-Dietz (TGFBR1/2 mutations): Constitutive TGF-β receptor signaling → excessive pathway activation
  3. Smooth muscle cell dysfunction: Loss of contractile phenotype, increased apoptosis, defective matrix synthesis
  4. Hemodynamic stress: Ascending aorta experiences highest wall tension (Laplace's law: Tension = Pressure × Radius); progressive dilation creates positive feedback loop
• Clinical implications: Weakened aortic wall → reduced tensile strength → predisposition to progressive dilatation → dissection/rupture

Q4: "Why is beta-blockade initiated BEFORE vasodilators in acute dissection management?"

Model Answer:

• Reflex tachycardia prevention: Vasodilators (nitroprusside, hydralazine) cause BP drop → baroreceptor-mediated reflex sympathetic activation → increased HR and contractility → increased dP/dt (rate of aortic pressure rise) → increased aortic wall shear stress → propagation of dissection
• Hemodynamic goal: Reduce BOTH blood pressure AND dP/dt (shear stress); dP/dt is proportional to heart rate and LV contractility
• Sequence:
  1. Beta-blocker FIRST (esmolol, labetalol, metoprolol) → target HR \u003c60 bpm
  2. THEN vasodilator (if SBP still \u003e120 mmHg despite beta-blockade)
• Exception: Labetalol (combined alpha/beta blocker) can be used as single agent (blocks both pathways simultaneously)
• Clinical significance: Failure to give beta-blocker first may paradoxically WORSEN dissection propagation despite lowering BP

Q5: "A patient with uncomplicated Type B aortic dissection - should you offer TEVAR or medical management? Discuss the evidence."

Model Answer:

• Historical approach: Medical management alone (beta-blocker, BP control)
• TEVAR rationale: Cover entry tear → promote false lumen thrombosis → improve aortic remodeling → reduce late aneurysm formation

Evidence:

• INSTEAD Trial (2013): Uncomplicated Type B; TEVAR + medical vs medical alone
  • "2-year outcomes: No difference in mortality (11.1% vs 6.9%, p=NS)"
  • "5-year outcomes (INSTEAD-XL): "
    • All-cause mortality: No difference (11.1% vs 19.3%, p=NS)
    • Aortic-specific mortality: Trend toward benefit (6.9% vs 19.3%, p=0.13)
    • Aortic remodeling: Significantly better with TEVAR (91.3% vs 19.4%, p\u003c0.001)
    • Progression to intervention: Lower with TEVAR (2.8% vs 46.3%)
• Recent meta-analyses (2024-2025): TEVAR reduces long-term mortality, aortic expansion, need for re-intervention

Current approach (per 2022 ACC/AHA Guidelines):

• Acute uncomplicated Type B: Medical management preferred
• Subacute uncomplicated Type B (2-90 days): Consider TEVAR in selected patients (young, low operative risk, favorable anatomy) for improved long-term aortic remodeling
• Chronic uncomplicated Type B: Medical management; TEVAR if aneurysm develops ≥5.5-6.0 cm

My approach: Uncomplicated Type B → initial medical management; discuss TEVAR with patient if young, healthy, favorable anatomy (proximal landing zone ≥2 cm); emphasize long-term benefit vs short-term procedural risk (5-10% mortality, 2-5% paraplegia, 3-5% stroke)

Q6: "What are the surgical thresholds for elective TAA repair? How do you justify these numbers?"

Model Answer: General population thresholds (2022 ACC/AHA Guidelines):

• Ascending TAA: ≥5.5 cm
• Descending TAA: ≥6.0 cm
• Growth rate: ≥0.5 cm/year (regardless of absolute size)

Lower thresholds:

• Marfan syndrome: ≥5.0 cm (ascending); consider 4.5 cm if additional risk factors (family history of dissection \u003c5 cm, rapid growth, aortic root Z-score \u003e3)
• Loeys-Dietz syndrome: ≥4.0-4.5 cm (more aggressive aortopathy; higher rupture risk at smaller diameters)
• Bicuspid aortic valve: ≥5.0 cm; consider 4.5 cm if other risk factors (coarctation, family history)
• Family history of dissection \u003c5 cm: ≥5.0 cm
• Concomitant cardiac surgery: ≥4.5 cm (replace ascending aorta during AVR/CABG)

Evidence basis:

• Yale TAA Outcomes Study (Davies et al., 2002): 5-year event rates (rupture/dissection/death):
  • 4.0-4.9 cm: 4% (0.8%/year)
  • 5.0-5.9 cm: 16% (3.2%/year)
  • ≥6.0 cm: 31% (6.2%/year)
• Operative mortality (elective, high-volume centers):
  • "Ascending aorta: 2-5%"
  • "Descending aorta (TEVAR): 2-5%"
  • "Descending aorta (open): 5-15%"

Risk-benefit analysis: 5.5 cm threshold balances ~3%/year rupture/dissection risk vs ~3% operative mortality at experienced centers. For genetic syndromes, dissection risk at smaller diameters justifies earlier intervention.

Q7: "A 45-year-old woman with Marfan syndrome and aortic root 4.2 cm is 8 weeks pregnant. What do you counsel her?"

Model Answer:

• Risk assessment: Aortic root 4.2 cm in Marfan + pregnancy is high risk

  • Dissection risk ~1% this pregnancy (50-100 times higher than general pregnant population)
  • 50% of dissections in women \u003c40 occur during pregnancy/postpartum
  • Hemodynamic stress peaks in third trimester and labor

• Counseling:

  • Significant maternal (dissection, death) and fetal (preterm delivery, fetal death) risks
  • "Pregnancy will increase aortic wall stress due to:"
    • Increased blood volume (30-50%)
    • Increased cardiac output (30-50%)
    • Hormonal changes (relaxin, estrogen) weakening aortic wall

• Options (patient choice):

  • Continue pregnancy with intensive surveillance vs termination

• If continuing pregnancy:

  • "Medications: Beta-blocker (labetalol preferred; avoid atenolol in first trimester) throughout pregnancy"
  • "Imaging: TTE every 4-8 weeks (more frequent if growth detected)"
  • "Multidisciplinary care: Maternal-fetal medicine, cardiology, cardiothoracic surgery, anesthesia"
  • "Activity restriction: Avoid strenuous activity, heavy lifting"
  • "Delivery planning: "
    • Cesarean delivery recommended (avoid Valsalva)
    • Epidural anesthesia (reduce pain, sympathetic surge)
    • Assisted second stage (forceps/vacuum to avoid pushing)
    • Tertiary center with cardiac surgery capability

• Postpartum: High-risk period continues 6 months; 33% of pregnancy-associated dissections occur postpartum

  • Continue beta-blockers
  • Serial imaging at 6 weeks, 3 months, 6 months
  • Contraception counseling (avoid estrogen-containing contraceptives; prefer progestin-only or barrier methods)

• Ideal scenario: If she were pre-pregnancy with aortic root \u003e4.0 cm, would recommend prophylactic repair before pregnancy (reduces dissection risk from 30-50% to 10-20%)

Q8: "How does the TEM classification differ from Stanford classification?"

Model Answer:

• TEM Classification (Type-Entry-Malperfusion) is a newer, more granular classification proposed by Sievers et al. (2020) to improve upon Stanford classification. [60]

Components:

1. Type (T):

   • Type A: Ascending aorta involved
   • Type B: Ascending aorta NOT involved
   • Type non-A-non-B: Isolated arch dissection (not extending into ascending or descending)

2. Entry (E): Location of primary intimal tear

   • E0: No identifiable entry tear (e.g., intramural hematoma)
   • E1: Entry in ascending aorta
   • E2: Entry in aortic arch
   • E3: Entry in descending thoracic aorta
   • E4: Entry in abdominal aorta

3. Malperfusion (M): Affected organs

   • M0: No malperfusion
   • M1: One organ system affected
   • M2: Two or more organ systems affected
   • Organs specified: c (cardiac/coronary), ce (cerebral), sp (spinal), vi (visceral/mesenteric), r (renal), p (peripheral/limb)

Example: Type A, E1, M2(c+vi) = Type A dissection with entry tear in ascending aorta and malperfusion of cardiac (coronary) and visceral (mesenteric) beds.

Advantages over Stanford:

• Prognostic value: Malperfusion category predicts mortality (M0: 10-15%; M1: 20-30%; M2: 40-60%)
• Treatment planning: Entry location guides surgical approach (e.g., E3 Type A may require elephant trunk vs standard ascending replacement)
• Outcome prediction: More granular risk stratification
• Research standardization: Enables better comparison across studies

Clinical relevance: While Stanford remains primary classification for acute management decisions (Type A → surgery; Type B → medical), TEM provides additional prognostic information and may guide surgical strategy, especially in complex cases. [60]

Q9: "What are the indications for cerebrospinal fluid drainage in aortic surgery?"

Model Answer:

• CSF drainage reduces risk of spinal cord ischemia (paraplegia/paraparesis) in thoracic and thoracoabdominal aortic surgery by improving spinal cord perfusion pressure.

Mechanism:

• Spinal cord perfusion pressure (SCPP) = Mean Arterial Pressure (MAP) - CSF Pressure
• Aortic cross-clamping reduces MAP; surgical manipulation increases CSF pressure → reduced SCPP → ischemia
• CSF drainage lowers CSF pressure → increases SCPP → reduces ischemia risk

Indications: [40,53]

1. Open descending/thoracoabdominal aortic repair (Class I recommendation)
2. TEVAR for extensive descending aortic disease:
   • Coverage of \u003e15-20 cm of aorta
   • Coverage of critical intercostal arteries (T8-L1)
   • Prior abdominal aortic repair (collateral circulation compromised)
   • Emergency TEVAR for rupture/dissection
3. Staged procedures (e.g., ascending + descending repair within short interval)
4. Re-do thoracic aortic surgery

Contraindications:

• Coagulopathy (INR \u003e1.5, platelets \u003c50,000)
• Local infection at lumbar puncture site
• Severe spinal deformity preventing safe access

Protocol:

• Timing: Insert before or at start of surgery; maintain 24-72 hours post-operatively
• Target CSF pressure: \u003c10 mmHg (some protocols \u003c12-15 mmHg)
• Drainage rate: Typically 10-15 mL/hour; adjust to maintain target pressure
• Monitoring: Hourly CSF pressure, drainage volume, neurological assessment

Complications (2-5% incidence):

• Subdural/intracranial hemorrhage (most serious; 1-3%)
• CSF leak at catheter site
• Meningitis/epidural abscess (\u003c1%)
• Post-dural puncture headache (10-15%)
• Catheter malfunction/dislodgement

Efficacy: Reduces paraplegia risk from 10-15% to 2-5% in high-risk thoracoabdominal surgery; benefit less clear in standard TEVAR. [40,53]

Q10: "Compare outcomes of TEVAR vs open repair for descending thoracic aortic aneurysm."

Model Answer:

Landmark Trial: Bavaria et al. (2007) - Multicenter comparative trial; TEVAR had lower 30-day mortality (2.1% vs 11.7%, p\u003c0.001), lower paraplegia (3% vs 14%), shorter hospital stay (median 6 vs 12 days). [40]

Selection criteria:

• TEVAR preferred if:

  • High surgical risk (age \u003e75, significant comorbidities)
  • Adequate anatomy (proximal/distal landing zones ≥2 cm, minimal tortuosity, suitable femoral access)
  • Isolated descending TAA

• Open repair preferred if:

  • Young, healthy patient (long-term durability)
  • Connective tissue disorder (Marfan, Loeys-Dietz) - high risk of endoleak, retrograde dissection with TEVAR
  • Inadequate landing zones (may require hybrid debranching + TEVAR)
  • Extensive thoracoabdominal disease requiring visceral artery reconstruction

Current approach: TEVAR is first-line for most descending TAA given lower perioperative morbidity/mortality. Open repair reserved for young/low-risk patients, connective tissue disorders, or unsuitable anatomy. [1,40,53]

---

Evidence & Guidelines

Major Guidelines

1. 2022 ACC/AHA Guideline for the Diagnosis and Management of Aortic Disease [1]

   • Comprehensive evidence-based recommendations for TAA and dissection
   • Class I recommendations: Type A dissection requires emergency surgery; Type B complicated dissection benefits from TEVAR; size-based thresholds for elective repair; lifelong surveillance post-dissection
   • Emphasis on institutional volume and multidisciplinary aortic teams

2. 2014 ESC Guidelines on the Diagnosis and Treatment of Aortic Diseases [43]

   • European perspective on aortic disease management
   • Similar recommendations to ACC/AHA with minor regional variations
   • Strong emphasis on genetic evaluation and family screening

3. 2010 ACCF/AHA/AATS/ACR/ASA/SCA/SCAI/SIR/STS/SVM Guidelines for Thoracic Aortic Disease [44]

   • Previous iteration of ACC/AHA guidelines; foundational evidence base
   • Established size criteria and surgical thresholds

Key Evidence

1. INSTEAD Trial (Investigation of Stent Grafts in Aortic Dissection): Randomized trial comparing TEVAR plus medical therapy vs. medical therapy alone for uncomplicated Type B dissection. No difference in 2-year outcomes, but 5-year follow-up showed improved aortic remodeling and trend toward lower mortality with TEVAR. [15]

2. INSTEAD-XL Trial: Extended follow-up (5 years) of INSTEAD trial. TEVAR group had improved aortic remodeling, lower rate of aortic expansion, and trend toward lower aortic-specific mortality. [15]

3. IRAD (International Registry of Acute Aortic Dissection): Prospective multinational registry of > 6,000 patients with acute aortic dissection. Established natural history, risk factors, and outcome predictors. [5,7,8]

4. VIRTUE Registry: Observational study of TEVAR for Type B dissection. Demonstrated safety and efficacy with 30-day mortality 5-10% and 5-year survival 70-80%. [40]

5. Yale TAA Outcomes Study: Large cohort study defining rupture and dissection risk based on TAA diameter. Established 5-year event rates: 4% (4.0-4.9 cm), 16% (5.0-5.9 cm), 31% (≥6.0 cm). Foundational data for surgical thresholds. [6]

6. Marfan Aortic Root Replacement Studies: Multiple cohort studies demonstrating benefit of prophylactic aortic root replacement at diameter 4.5-5.0 cm in Marfan syndrome; reduces dissection and death from 30-50% (if untreated) to 10-20% (if repaired). [13,14,41]

7. Beta-Blocker Trials in Marfan Syndrome: Landmark RCT showing beta-blockers slow aortic root growth and reduce dissection risk in Marfan patients. [41] Extended benefit likely applies to other TAA etiologies.

8. ARB Trials (COMPARE, others): Mixed results for ARBs in Marfan syndrome; some show benefit, others show no difference vs. beta-blockers alone. [42] Current role: alternative or adjunct to beta-blockers.

9. Volume-Outcome Studies: Multiple studies demonstrate 40-50% lower mortality at high-volume centers (> 20 cases/year) compared to low-volume centers (less than 5 cases/year) for complex aortic surgery. [17]

---

Patient & Family Information

What is a Thoracic Aortic Aneurysm?

A thoracic aortic aneurysm (TAA) is a bulge or widening in the main blood vessel (aorta) that carries blood from your heart to the rest of your body. The aorta in your chest normally measures 2-3 cm (about 1 inch) in diameter. When it grows larger than 4-5 cm, it is called an aneurysm.

Most people with TAA have no symptoms. The aneurysm is usually discovered by accident on a chest X-ray or CT scan done for another reason.

What is Aortic Dissection?

Aortic dissection is a tear in the inner lining of the aorta. Blood enters this tear and separates the layers of the aortic wall, creating a false channel. This is a life-threatening emergency that requires immediate treatment.

Symptoms of Aortic Dissection

If you experience these symptoms, call emergency services (911) immediately:

• Sudden, severe chest or back pain that feels like tearing or ripping
• Pain that moves from chest to back or abdomen
• Feeling faint or loss of consciousness
• Difficulty breathing
• Sudden weakness or inability to move arms or legs
• Different blood pressure in your two arms

Aortic dissection is a medical emergency. Every minute counts. Do not wait or try to "see if it gets better."

How is TAA Diagnosed?

• Echocardiogram (ultrasound of the heart): Measures aortic size
• CT scan with contrast dye: Detailed images of entire aorta
• MRI scan: Alternative to CT scan, no radiation

Treatment Options

For Unruptured TAA (Not Emergency)

Medications:

• Beta-blockers to lower heart rate and blood pressure
• Other blood pressure medications
• Goal: Keep blood pressure under 130/80 mmHg

Monitoring:

• Repeat imaging every 6-12 months to measure aneurysm size
• Surgery recommended if aneurysm grows to 5.5 cm or larger (5.0 cm if you have a genetic condition or bicuspid aortic valve)

Surgery (when aneurysm is large enough or growing quickly):

• Replace weakened section of aorta with artificial tube (graft)
• Open surgery through chest or minimally invasive stent-graft (TEVAR) depending on location
• Excellent outcomes when done electively at experienced centers

For Aortic Dissection (Emergency)

Type A dissection (involves upper part of aorta):

• Emergency open-heart surgery to replace torn section
• Surgery needed immediately; without surgery, 50% die within 2 days
• With surgery, 70-80% survive long-term

Type B dissection (involves lower part of aorta):

• Medications to control blood pressure and heart rate (if uncomplicated)
• Stent-graft (TEVAR) if dissection causes complications (organ damage, ongoing pain, rupture)

After Treatment

Lifelong care required:

• Take blood pressure medications every day
• Regular imaging (CT or MRI) to monitor aorta
• Keep blood pressure controlled (target less than 130/80 mmHg)
• Avoid heavy lifting and straining
• Family members may need screening

Lifestyle Modifications

Do:

• Take all medications as prescribed
• Monitor your blood pressure at home
• Light to moderate exercise (walking, swimming) as approved by doctor
• Maintain healthy weight
• Manage stress

Avoid:

• Smoking (causes aneurysms to grow faster)
• Cocaine and stimulant drugs
• Heavy weightlifting or straining (increases blood pressure suddenly)
• Poorly controlled high blood pressure

Genetic Considerations

Some TAA and dissections run in families. If you have a family history or genetic condition (Marfan syndrome, Loeys-Dietz syndrome, Ehlers-Danlos syndrome, bicuspid aortic valve), your children and siblings should be screened with echocardiogram or CT scan.

Resources and Support

• American Heart Association: www.heart.org - Information on aortic disease
• Marfan Foundation: www.marfan.org - For genetic aortic conditions
• Aortic Dissection Awareness: www.aorticdissectionawareness.org - Patient stories and support
• British Heart Foundation: www.bhf.org.uk - UK resource
• John Ritter Foundation: www.johnritterfoundation.org - Aortic disease awareness

---

References

1. Isselbacher EM, Preventza O, Hamilton Black J 3rd, et al. 2022 ACC/AHA Guideline for the Diagnosis and Management of Aortic Disease: A Report of the American Heart Association/American College of Cardiology Joint Committee on Clinical Practice Guidelines. J Am Coll Cardiol. 2022;80(24):e223-e393. PMID: 36334952

2. Tsai TT, Nienaber CA, Eagle KA. Acute aortic syndromes. Circulation. 2005;112(24):3802-3813. PMID: 16344407

3. Nienaber CA, Clough RE. Management of acute aortic dissection. Lancet. 2015;385(9970):800-811. PMID: 25662791

4. Olsson C, Thelin S, Ståhle E, Ekbom A, Granath F. Thoracic aortic aneurysm and dissection: increasing prevalence and improved outcomes reported in a nationwide population-based study of more than 14,000 cases from 1987 to 2002. Circulation. 2006;114(24):2611-2618. PMID: 17145990

5. Hagan PG, Nienaber CA, Isselbacher EM, et al. The International Registry of Acute Aortic Dissection (IRAD): new insights into an old disease. JAMA. 2000;283(7):897-903. PMID: 10685714

6. Davies RR, Goldstein LJ, Coady MA, et al. Yearly rupture or dissection rates for thoracic aortic aneurysms: simple prediction based on size. Ann Thorac Surg. 2002;73(1):17-27. PMID: 11834007

7. Khan IA, Nair CK. Clinical, diagnostic, and management perspectives of aortic dissection. Chest. 2002;122(1):311-328. PMID: 12114376

8. Trimarchi S, Eagle KA, Nienaber CA, et al. Role of age in acute type A aortic dissection outcome: report from the International Registry of Acute Aortic Dissection (IRAD). J Thorac Cardiovasc Surg. 2010;140(4):784-789. PMID: 20579669

9. Tsai TT, Fattori R, Trimarchi S, et al. Long-term survival in patients presenting with type B acute aortic dissection: insights from the International Registry of Acute Aortic Dissection. Circulation. 2006;114(21):2226-2231. PMID: 17101856

10. Shiga T, Wajima Z, Apfel CC, Inoue T, Ohe Y. Diagnostic accuracy of transesophageal echocardiography, helical computed tomography, and magnetic resonance imaging for suspected thoracic aortic dissection: systematic review and meta-analysis. Arch Intern Med. 2006;166(13):1350-1356. PMID: 16831999

11. Sodeck G, Domanovits H, Schillinger M, et al. D-dimer in ruling out acute aortic dissection: a systematic review and prospective cohort study. Eur Heart J. 2007;28(24):3067-3075. PMID: 17981829

12. Nazerian P, Mueller C, Soeiro AM, et al. Diagnostic Accuracy of the Aortic Dissection Detection Risk Score Plus D-Dimer for Acute Aortic Syndromes: The ADvISED Prospective Multicenter Study. Circulation. 2018;137(3):250-258. PMID: 29030346

13. Milewicz DM, Braverman AC, De Backer J, et al. Marfan syndrome. Nat Rev Dis Primers. 2021;7(1):64. PMID: 34475381

14. Pyeritz RE. Marfan syndrome: 30 years of research equals 30 years of additional life expectancy. Heart. 2009;95(3):173-175. PMID: 19144877

15. Nienaber CA, Kische S, Rousseau H, et al. Endovascular repair of type B aortic dissection: long-term results of the randomized investigation of stent grafts in aortic dissection trial. Circ Cardiovasc Interv. 2013;6(4):407-416. PMID: 23922146

16. Hansen MS, Nogareda GJ, Hutchison SJ. Frequency of and inappropriate treatment of misdiagnosis of acute aortic dissection. Am J Cardiol. 2007;99(6):852-856. PMID: 17350381

17. Hughes GC, Zhao Y, Rankin JS, et al. Effects of institutional volumes on operative outcomes for aortic root replacement in North America. J Thorac Cardiovasc Surg. 2013;145(1):166-170. PMID: 22424519

18. Clouse WD, Hallett JW Jr, Schaff HV, et al. Improved prognosis of thoracic aortic aneurysms: a population-based study. JAMA. 1998;280(22):1926-1929. PMID: 9851478

19. Spittell PC, Spittell JA Jr, Joyce JW, et al. Clinical features and differential diagnosis of aortic dissection: experience with 236 cases (1980 through 1990). Mayo Clin Proc. 1993;68(7):642-651. PMID: 8350637

20. Mehta RH, Manfredini R, Hassan F, et al. Chronobiological patterns of acute aortic dissection. Circulation. 2002;106(9):1110-1115. PMID: 12196337

21. Lederle FA, Johnson GR, Wilson SE, et al. The aneurysm detection and management study screening program: validation cohort and final results. Arch Intern Med. 2000;160(10):1425-1430. PMID: 10826454

22. Michelena HI, Khanna AD, Mahoney D, et al. Incidence of aortic complications in patients with bicuspid aortic valves. JAMA. 2011;306(10):1104-1112. PMID: 21917581

23. Tzemos N, Therrien J, Yip J, et al. Outcomes in adults with bicuspid aortic valves. JAMA. 2008;300(11):1317-1325. PMID: 18799444

24. MacCarrick G, Black JH 3rd, Bowdin S, et al. Loeys-Dietz syndrome: a primer for diagnosis and management. Genet Med. 2014;16(8):576-587. PMID: 24577266

25. Pepin M, Schwarze U, Superti-Furga A, Byers PH. Clinical and genetic features of Ehlers-Danlos syndrome type IV, the vascular type. N Engl J Med. 2000;342(10):673-680. PMID: 10706896

26. Carlson M, Silberbach M. Dissection of the aorta in Turner syndrome: two cases and review of 85 cases in the literature. J Med Genet. 2007;44(12):745-749. PMID: 17704260

27. Milewicz DM, Dietz HC, Miller DC. Treatment of aortic disease in patients with Marfan syndrome. Circulation. 2005;111(11):e150-157. PMID: 15781745

28. Evans JM, O'Fallon WM, Hunder GG. Increased incidence of aortic aneurysm and dissection in giant cell (temporal) arteritis. A population-based study. Ann Intern Med. 1995;122(7):502-507. PMID: 7872584

29. Eagle KA, Isselbacher EM, DeSanctis RW. Cocaine-related aortic dissection in perspective. Circulation. 2002;105(13):1529-1530. PMID: 11927515

30. Goland S, Barakat M, Khatri N, Elkayam U. Pregnancy in Marfan syndrome: maternal and fetal risk and recommendations for patient assessment and management. Cardiol Rev. 2009;17(6):253-262. PMID: 19829174

31. Ehrman JK, Fernandez AB, Myers J, et al. Aortic Aneurysm: Diagnosis, Management, Exercise Testing, and Training. J Cardiopulm Rehabil Prev. 2020;40(4):215-223. PMID: 32604251

32. Rabkin SW. The Role Matrix Metalloproteinases in the Production of Aortic Aneurysm. Prog Mol Biol Transl Sci. 2017;147:239-265. PMID: 28413035

33. Gomez D, Owens GK. Smooth muscle cell phenotypic switching in atherosclerosis. Cardiovasc Res. 2012;95(2):156-164. PMID: 22406749

34. van Dorst DCH, de Wagenaar NP, van der Pluijm I, et al. Transforming Growth Factor-β and the Renin-Angiotensin System in Syndromic Thoracic Aortic Aneurysms: Implications for Treatment. Cardiovasc Drugs Ther. 2021;35(6):1233-1252. PMID: 33277608

35. Humphrey JD. Cardiovascular Solid Mechanics: Cells, Tissues, and Organs. Springer-Verlag New York; 2002.

36. Tsagakis K, Pacini D, Di Bartolomeo R, et al. Arch replacement and downstream stent grafting in complex aortic dissection: first results of an international registry. Eur J Cardiothorac Surg. 2011;39(1):87-94. PMID: 20643559

37. Pape LA, Awais M, Woznicki EM, et al. Presentation, Diagnosis, and Outcomes of Acute Aortic Dissection: 17-Year Trends From the International Registry of Acute Aortic Dissection. J Am Coll Cardiol. 2015;66(4):350-358. PMID: 26205591

38. Erbel R, Engberding R, Daniel W, Roelandt J, Visser C, Rennollet H. Echocardiography in diagnosis of aortic dissection. Lancet. 1989;1(8636):457-461. PMID: 2563861

39. Jimenez-Altayo F, Meirelles T, Crosas-Molist E, et al. Redox stress in Marfan syndrome: Dissecting the role of the NADPH oxidase NOX4 in aortic aneurysm. Free Radic Biol Med. 2018;118:44-58. PMID: 29458196

40. Bavaria JE, Appoo JJ, Makaroun MS, Verter J, Yu ZF, Mitchell RS. Endovascular stent grafting versus open surgical repair of descending thoracic aortic aneurysms in low-risk patients: a multicenter comparative trial. J Thorac Cardiovasc Surg. 2007;133(2):369-377. PMID: 17258566

41. Shores J, Berger KR, Murphy EA, Pyeritz RE. Progression of aortic dilatation and the benefit of long-term beta-adrenergic blockade in Marfan's syndrome. N Engl J Med. 1994;330(19):1335-1341. PMID: 8152445

42. Groenink M, den Hartog AW, Franken R, et al. Losartan reduces aortic dilatation rate in adults with Marfan syndrome: a randomized controlled trial. Eur Heart J. 2013;34(45):3491-3500. PMID: 23999449

43. Erbel R, Aboyans V, Boileau C, et al. 2014 ESC Guidelines on the diagnosis and treatment of aortic diseases. Eur Heart J. 2014;35(41):2873-2926. PMID: 25173340

44. Hiratzka LF, Bakris GL, Beckman JA, et al. 2010 ACCF/AHA/AATS/ACR/ASA/SCA/SCAI/SIR/STS/SVM guidelines for the diagnosis and management of patients with Thoracic Aortic Disease. Circulation. 2010;121(13):e266-369. PMID: 20233780

45. Carrel T, Sundt TM, von Kodolitsch Y, et al. Acute aortic dissection. Lancet. 2023;401(10372):773-788. doi:10.1016/S0140-6736(22)01970-5 PMID: 36640801

46. Hameed I, Cifu AS, Vallabhajosyula P. Management of Thoracic Aortic Dissection. JAMA. 2023;329(14):1182-1191. doi:10.1001/jama.2023.0265 PMID: 36795378

47. Sorber R, Hicks CW. Diagnosis and Management of Acute Aortic Syndromes: Dissection, Penetrating Aortic Ulcer, and Intramural Hematoma. Curr Cardiol Rep. 2022;24(3):209-216. doi:10.1007/s11886-022-01642-3 PMID: 35029783

48. Ganizada BH, Veltrop RJA, Akbulut AC, et al. Unveiling cellular and molecular aspects of ascending thoracic aortic aneurysms and dissections. Basic Res Cardiol. 2024;119(3):349-378. doi:10.1007/s00395-024-01053-1 PMID: 38700707

49. Berger T, Dumfarth J, Kreibich M, et al. Thoracic aortic aneurysm. Nat Rev Dis Primers. 2025;11(1):9. doi:10.1038/s41572-025-00617-2 PMID: 40341396

50. Rylski B, Schilling O, Czerny M. Acute aortic dissection: evidence, uncertainties, and future therapies. Eur Heart J. 2023;44(10):813-821. doi:10.1093/eurheartj/ehac757 PMID: 36540036

51. Qazi SU, Zaide DB, Fatima U, et al. Long term outcomes of thoracic endovascular repair versus optimal medical therapy for uncomplicated Stanford type B aortic dissection: a systematic review and meta-analysis. Future Cardiol. 2025;21(1):1-15. doi:10.1080/14796678.2025.2557765 PMID: 40923587

52. Motawea KR, Rouzan SS, Elhalag RH, et al. Efficacy of thoracic endovascular aortic repair versus medical therapy for treatment of type B aortic dissection. BMC Surg. 2024;24(1):273. doi:10.1186/s12893-024-02555-4 PMID: 39261808

53. Awiwi MO, Kandemirli VB, Kokash D, et al. Complications of thoracic endovascular aneurysm repair (TEVAR): A pictorial review. Curr Probl Diagn Radiol. 2024;53(6):708-719. doi:10.1067/j.cpradiol.2024.05.018 PMID: 38777715

54. Zhou Z, Cecchi AC, Prakash SK, et al. Risk Factors for Thoracic Aortic Dissection. Genes (Basel). 2022;13(10):1814. doi:10.3390/genes13101814 PMID: 36292699

55. Braverman AC, Mittauer E, Harris KM, et al. Clinical Features and Outcomes of Pregnancy-Related Acute Aortic Dissection. JAMA Cardiol. 2021;6(1):58-66. doi:10.1001/jamacardio.2020.4876 PMID: 33052376

56. Zhu Y, Lingala B, Baiocchi M, et al. Type A Aortic Dissection-Experience Over 5 Decades: JACC Historical Breakthroughs in Perspective. J Am Coll Cardiol. 2020;76(14):1703-1713. doi:10.1016/j.jacc.2020.07.061 PMID: 33004136

57. Senser EM, Misra S, Henkin S. Thoracic Aortic Aneurysm: A Clinical Review. Cardiol Clin. 2021;39(4):505-515. doi:10.1016/j.ccl.2021.06.003 PMID: 34686263

58. Sen I, Erben YM, Franco-Mesa C, et al. Epidemiology of aortic dissection. Semin Vasc Surg. 2021;34(1):10-17. doi:10.1053/j.semvascsurg.2021.02.003 PMID: 33757630

59. Juraszek A, Czerny M, Rylski B. Update in aortic dissection. Trends Cardiovasc Med. 2022;32(3):152-159. doi:10.1016/j.tcm.2021.08.008 PMID: 34411744

60. Sievers HH, Rylski B, Czerny M, et al. Aortic dissection reconsidered: type, entry site, malperfusion classification adding clarity and enabling outcome prediction. Interact Cardiovasc Thorac Surg. 2020;30(3):451-457. doi:10.1093/icvts/ivz281 PMID: 31755925

61. Verma R, Cohen G, Colbert J, et al. Bicuspid aortic valve associated aortopathy: 2022 guideline update. Curr Opin Cardiol. 2023;38(2):96-102. doi:10.1097/HCO.0000000000001020 PMID: 36718616

62. Chandiramani A, Al-Tawil M, Elleithy A, et al. Organ-specific malperfusion in acute type A aortic dissection: epidemiological meta-analysis of incidence rates. BJS Open. 2024;8(6):zrae146. doi:10.1093/bjsopen/zrae146 PMID: 39792052

---